Module 6: Bone & Joint Disorders Flashcards by Mr. Bobbits

Osteoar_______:

Characterized by slow onset, usually after the age of 50 and is associated with absent or minimal inflammation. Pain in the hips, knees and hands (symmetrical or asymmetric) +/- bony enlargements. A hall mark is morning stiffness lasting < 30 minutes.

Osteoarthritis

How well did you know this?

Not at all

Perfectly

Osteoa________:

Non-pharmacological approaches include Rest, Weight loss (if overweight), Exercise (low impact, aerobic, strength training), Heat / Ice, Occupational/physical therapy (OT/PT) and Surgery

Osteoarthritis

How well did you know this?

Not at all

Perfectly

A___:

First line therapy for mild to moderate osteoarthritis

(Recognized by American College of Rheumatology, European League Against Rheumatism, Academy of Orthopedic Surgeons)

APAP

How well did you know this?

Not at all

Perfectly

A___: First line therapy for mild to moderate osteoarthritis.

- - 325 to 650 mg by mouth every 4 to 6 hours
4 g per day
2-3 g per day, if patient is >75 years (also recommended by some clinicians for the general population to reduce the risk of hepatic injury) (AGS 2009)
2 g per day, if heavy alcohol use, malnutrition, fasting, low body weight, advanced age, febrile illness, select liver disease, and use of drugs that interact with acetaminophen metabolism may increase risk of hepatotoxicity (Hamilton 2019b; Hayward 2016; Larson 2007).

APAP

How well did you know this?

Not at all

Perfectly

Regarding A___ and OA:

A common reason for inadequate response is failure to use sufficient dose for adequate duration (4-6 week). Some patients may require scheduled (ATC) dosing vs PRN dosing

APAP

How well did you know this?

Not at all

Perfectly

Regarding OA:

A___ should be tried initially at an adequate dose and duration before considering an NSAID.

APAP

How well did you know this?

Not at all

Perfectly

A___ is considered as effective as NSAID for mild-moderate OA pain

APAP

How well did you know this?

Not at all

Perfectly

Regarding A___ and OA:

Consider alternative pharmacologic therapy if inadequate response or in presence of severe pain and/or inflammation, based on relative efficacy and safety, as well as concomitant medications and comorbidities

APAP

How well did you know this?

Not at all

Perfectly

N_____ for OA:

a reasonable adjunct or alternative therapy when APAP fails to provide an acceptable analgesic response (despite adequate dose / duration / ATC dosing) or if there is an inflammatory component. ACR conditionally recommends use of oral N____s as an option for the initial management of moderate-severe OA.

NSAIDs

How well did you know this?

Not at all

Perfectly

All N_____ (regarding OA) are equally effective when used at comparable doses.

NSAIDs

How well did you know this?

Not at all

Perfectly

Regarding OA:

selection of a specific oral N____ should be based on patient preference, previous response, tolerability, side-effect profile, dosing frequency, cost, and underlying GI risk.

NSAID

How well did you know this?

Not at all

Perfectly

Regarding N____s and OA:

use lowest effective dose and avoid long-term use if possible

NSAID

How well did you know this?

Not at all

Perfectly

Regarding OA:

C__-2 i_________ are equally effective, but no more effective than non selective NSAIDs and should be reserved for those at high risk for GI events.

COX-2 inhibitors

How well did you know this?

Not at all

Perfectly

Regarding OA:

Gastroprotection or COX2:

Cox2 inhibitors may be associated with increase CV risk
Non-selective N____s such as diclofenac also have increased CV risk vs other non-selective N____s

NSAIDs

How well did you know this?

Not at all

Perfectly

Regarding OA and N_____:

Acetaminophen in combination with low-dose naproxen or ibuprofen could help to control pain and reduce GU risk.

NSAIDs

How well did you know this?

Not at all

Perfectly

Regarding OA:

use N_____ (including nonselective and COX-2-selective agents) with caution if cardiovascular risk factors are present

NSAIDs

How well did you know this?

Not at all

Perfectly

Regarding OA:

Glu________ and chon_______:

In the landmark GAIT trial sponsored by NIH, the use of this was no more effective than placebo in decreasing pain. However, in the context of study limitations, there may be a modest reduction in pain and improved mobility in some patients. They may also slow disease progression, although the clinical impact is unclear at this time.

Can be extrapolated to other remedies such as turmeric (curcumin), white willow bark, MSM, SAMe
As over the counter supplements, it is important to note that they are not regulated by the FDA

Glucosamine and chondroitin

How well did you know this?

Not at all

Perfectly

Regarding Intraarticular Injections and O_:

May be considered as an option in the initial management (ACR conditional recommendation), especially in patients with moderate-to-severe pain refractory to oral analgesic/anti-inflammatory agents

How well did you know this?

Not at all

Perfectly

Regarding intraarticular injections and O_:

Corticosteroids:

Onset in days, but duration does not persist for beyond 4 weeks. Safe frequency of injection is not an absolute number but varies according to the risk to chondrocyte viability and cartilage depth inherent to each disease. Serial injections (every three months) are discouraged due to potential negative effects on the progression of cartilage damage in knee OA patients

The use of systemic corticosteroids is discouraged in OA

How well did you know this?

Not at all

Perfectly

Regarding intraarticular injections and O_:

Hyaluronic acid:

Viscous substance believed to facilitate joint lubrication and shock absorption
Effect persists for longer than the residence time in the synovium
Greater pain relief than corticosteroids, but longer time to onset

How well did you know this?

Not at all

Perfectly

Regarding O_:

Tramadol / Opioids - Reserved for moderate or severe pain which impairs function or quality of life, for which potential benefits outweigh risks, and for which no alternative has better risk/benefit profile, patients unresponsive to other therapies or when other therapies are contraindicated

How well did you know this?

Not at all

Perfectly

Regarding Ost__a_______s and pain:

Opioids (including tramadol) should be initiated with short-acting agents at low doses and titrated to the lowest effective dose
Opioids (including tramadol) should be combined with acetaminophen or NSAIDs to reduce the opioid requirement
Clinicians should establish realistic pain and function goals
response to opioid therapy should be assessed within 1 to 4 weeks of initiation or dose increase and every 3 months thereafter

How well did you know this?

Not at all

Perfectly

Tram____ (med, regarding OA):

weak μ receptor agonist, serotonin re-uptake inhibitor, nor-epinephrine re-uptake inhibitor

Increase seizure risk
Serotonin syndrome
Adverse effects: similar to opioids

Tramadol

How well did you know this?

Not at all

Perfectly

S___ (duloxetine) - FDA approved for the management of chronic musculoskeletal pain, including OA

SNRI

How well did you know this?

Not at all

Perfectly

Regarding dul_______ (SNRI) and OA pain: May be of benefit in those with concomitant neuropathic pain - use not recommended if hepatic insufficiency, excessive alcohol use, or severe renal impairment (creatine clearance < 30 mL/minute) - geriatric patients may be at greater risk for clinically important hyponatremia - urinary hesitation and urinary retention have been reported - orthostatic hypotension reported, especially within first week of therapy - Concomitant use with tramadol should be pursued cautiously owing to an increased risk of serotonin syndrome.

duloxetine

dulox_____ (SNRI) and OA: Concomitant use with tramadol should be pursued cautiously owing to an increased risk of serotonin syndrome.

Duloxetine

Ost__p______ is a skeletal disease characterized by Low bone density, decreased bone strength and deterioration of bone micro-architecture

Osteoporosis

Regarding Osteop______: The key players involve vitamin D, PTH, calcitonin, calcium and FGF23

Osteoporosis

Regarding Osteop______: Involves men and women to different extent and with different underlying pathologies. - ♀ Accelerated bone loss as a result of loss of estrogen - ♂ Age or secondary cause (hypogonadism)is usually the most contributing factors to disease

Osteoporosis

Regarding O___________: Bone healthy lifestyle including exercise, no smoking, limiting EToH (<3 drinks/d), limiting caffeine and fall prevention measures, calcium and vitamin D to SUPPLEMENT DIETARY SOURCES

Osteoporosis

Regarding Osteoporosis: Calcium (not all salts provide the same amount of elemental calcium or have the same absorption profile). Remember: It's the elemental Ca that counts! C______ c________ - 40% elemental calcium - Available in tablet, chewable, and liquid formulations - Dose: 500-600mg taken with food - Acid dependent disintegration and dissolution

Calcium carbonate

Regarding Osteoporosis: Calcium (not all salts provide the same amount of elemental calcium or have the same absorption profile). Remember: It's the elemental Ca that counts! Cal____ ci____e - 21% elemental calcium - Available in tablet and chewable formulations - Dose: 200-625mg with or without food - Acid independent absorption - Who would benefit from calcium citrate vs calcium carbonate? - Recommendations of NOF, IOM, ACCE

Calcium citrate

Acid dependent disintegration and dissolution. Citrate or Carbonate?

Calcium carbonate

Acid independent absorption. Citrate or Carbonate?

Calcium citrate

Regarding v______ D and osteoporosis: - OTC: Vit D3 (Cholecalciferol) dose 200-1000 IU daily -- Available as individual supplement (200, 400, 1000, 2000, 5000 IU), in MVI or in combination with calcium supplements - RX: Vit D2 (Ergocalciferol) 50,000 IU weekly or monthly based on 25(OH)D concentrations -- Goal: serum 25-OH vit D > 30 ng/mL

Vitamin D

Pharmacological therapy regarding osteop______: The NOF recommends that all men and women older than 50 years be considered for pharmacologic treatment if they meet any of the following criteria: - (a) history of hip or vertebral fracture - (b) T-score –2.5 or less at femoral neck or spine - (c) osteopenia and at least a 3% 10-year probability of hip fracture or at least a 20% 10-year probability of major o___________-related fracture as determined by FRAX.

Osteoporosis

Calcium and Vitamin D supplement should be added to all drug therapy regimens for o___________ to increase bone density and decrease the risk of hip and vertebral fractures.

osteoporosis

Regarding osteoporosis: Bisph_________s: Of the antiresorptive agents, these consistently provide greatest fracture risk reduction and BMD increases. - ≈ ½ of absorbed drug accumulates in bone, Remainder of absorbed drug eliminated renally.

Bisphosphonates

Regarding osteoporosis and B______________: Select CIs/ADRs: - oral agents contraindicated in patients who cannot remain upright or who have esophageal abnormalities - risk of osteonecrosis of the jaw - Contraindicated in renal insufficiency or failure (CrCl < 30-35 ml/min) - increased risk of Afib with zolendronic acid

Bisphosphonates

Regarding o___________: Counseling for oral agents: - Must be taken on an empty stomach, first thing in the morning, with 8 ounces of plain water (no other liquid). - After taking this medication, patients must wait at least 60 minutes before eating, drinking or taking any other medication. - Patients must remain upright for at least one hour after taking the medication

Osteoporosis

Regarding osteop______: Patients should still be advised of the importance Ca and vitamin D and weight bearing exercise

Osteoporosis

Regarding osteoporosis: Specific agents have varying indications. For example: iband____te is indicated only in women for prevention and treatment of OP and has no indication in men or for GIOP (glucocorticoid-induced osteoporosis).

ibandronate

Regarding osteoporosis and b______________: - Typical duration of treatment with bisphosphonate is 3-5 years - Long-term efficacy of bisphosphonates are not known, but safety data exists for use >10 years

Bisphosphonates

Regarding o___________: Estrogens/HRT: Estrogen deficiency is associated with a gap between bone resorption and bone formation. While there are multiple possible mechanisms for this, estrogen effects on decreasing osteoblast apoptosis, oxidative stress, and osteoblastic NF-κB activity appear to be key mediators of the ability of estrogen to maintain bone formation.

osteoporosis

Regarding o____p______: Estrogen/hormone therapy is approved by the FDA for the prevention of *this*, relief of vasomotor symptoms, and vulvovaginal atrophy associated with menopause. Refer back to Men's/women's health. Estrogen must be used in combination with a progestin for women with an intact uterus

osteoporosis

When ET/HT use is considered solely for prevention of osteop______, the FDA recommends that approved non-estrogen treatments should first be carefully considered

osteoporosis

Regarding osteoporosis and the use of estr____ as treatment: The study was halted early despite demonstrated reduction in fracture because it was also shown - increase risk of heart disease - increase risk of stroke - increase risk of blood clots in lungs - increase risk of breast cancer - increased endometrial cancer - increase in dementia

estrogen

Regarding osteoporosis: Because of the risks, E_/H_ should be used in the lowest effective doses for the shortest duration to treat moderately severe menopausal symptoms and should be considered primarily for women within the first few years of menopause. - lower doses of transdermal estrogen may be preferred route of administration in women who are older, or those with metabolic syndromes such as fatty liver or hypertriglyceridemia with risk of pancreatitis - transdermal estrogen is preferred in smokers

ET/HT

Regarding o___ep______ and ET/HT: Patients should still be advised of the importance Ca and vitamin D and weight bearing exercise

osteoporosis

SERMs (ralox_____): FDA-approved for the prevention and treatment of osteoporosis in postmenopausal women

raloxifene

SERMs (ralo_____e): Also indicated for the reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis

raloxifene

SERMs (ralox_____): Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density (BMD) and decreases fracture incidence

raloxifene

SERMs (ralox_____): Preclinical data demonstrate that raloxifene is an estrogen antagonist in uterine and breast tissues.

raloxifene

SERMs (ralo_____e): (+) risk of VTE or previous history of VTE is contraindication to therapy, Pregnancy Category X, Slight increase in TG and fatal stroke (black box warning) This medication can treat and prevent osteoporosis in women who have gone through menopause

raloxifene

SERMs (ralox____e): Patients should still be advised of the importance Ca and vitamin D and weight bearing exercise

raloxifene

Conj______ estr_____/Bazed____ene: FDA approved for women who suffer from moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause - B___________ component reduces the risk of endometrial hyperplasia that can occur with the estrogen. Therefore progestins do not need to be taken - See estrogen precautions - - Like other products containing estrogen, it should be used for the shortest duration consistent with treatment goals and risks for the individual woman. - - When using this drug only for the prevention of osteoporosis, such use should be limited to women who are at significant risk of osteoporosis and only after carefully considering alternatives that do not contain estrogen.

Conjugated estrogens/Bazedoxifene:

Calc______: FDA approved for the treatment of osteoporosis in women who are 5 years past menopause - Less robust decrease in reduction of fracture (3rd line therapy) - Due to the possible association between malignancy and c_________-salmon use, the need for continued therapy should be re-evaluated on a periodic basis.

Calcitonin

Advantages of Calc______ (Safety): - No increased risk of breast and uterine cancer or VTE - No renal restrictions

Calcitonin

Advantages of Calcit____ (Efficacy): - Increased BMD - Decrease in vertebral fractures - analgesic effect on bone pain associated with acute fractures

Calcitonin

Disadvantages of Calc_____n (Efficacy): - Less robust decrease in reduction of fracture (3rd line therapy) - no decreased in nonvertebral or hip fracture

Calcitonin

Disadvantages of Calci_____ (Tolerability): Nasal: rhinitis, mucosal ulceration (rare), backache, HA SQ: nausea, local inflammatory response, flushing, backache, HA

Calcitonin

Disadvantages of Calc_____n (Simplicity): - nasal spray once daily - SQ injections every other day

Calcitonin

Disadvantages of Cal_______ (Safety): - Allergenicity (derived from salmon)

Calcitonin

Denos____: First line therapy and should be considered in those that cannot tolerate bisphosphonates - Treatment of post-menopausal osteoporosis - Treatment of osteoporosis in men at high risk of fracture, defined as history of osteoporotic fracture or multiple risk factors for fracture. - Treatment in women with breast cancer on aromatase inhibitor therapies and in men receiving gonadotropin-reducing hormone treatment for prostate cancer - Treatment of osteoporosis in postmenopausal women and men who have failed or are intolerant of other available osteoporosis therapies. - Prevention of OP NOT an approved indication

Denosumab

Deno_____: - Treatment of post-menopausal osteoporosis

Denosumab

Deno_____: - Treatment of osteoporosis in men at high risk of fracture, defined as history of osteoporotic fracture or multiple risk factors for fracture.

Denosumab

Denos____: - Treatment in women with breast cancer on aromatase inhibitor therapies and in men receiving gonadotropin-reducing hormone treatment for prostate cancer

Denosumab

Deno____b: - Treatment of osteoporosis in postmenopausal women and men who have failed or are intolerant of other available osteoporosis therapies.

Denosumab

Deno_____: - Prevention of OP NOT an approved indication

Denosumab

Denos___b may cause hypocalcemia. Hypocalcemia must be corrected before starting denosumab.

Denosumab

Denos____: Administered by a health professional, 60 mg every 6 months as a subcutaneous injection. - Dose adjustment not needed in renal patients

Denosumab

Denos___b: increased the risk of serious skin infections (cellulitis) and skin rash.

Denosumab

Disadvantages of Deno_____ (Safety): - Patients with CrCl <30: monitor for hypocalcemia

Denosumab

Disadvantages of Denos____ (Tolerability): - Fatigue, HA, dermatitis, rash, eczema, cellulitis, myalgia, limb pain, peripheral edema, angina, hypocalcemia, hypercholesterolemia, ONJ

Denosumab

Disadvantages of Deno_____ (Price): - very expensive - $1,650 per year plus the cost associated with an office visit

Denosumab

Disadvantages of Denos____ (Simplicity): - Patient must come to provider for injection

Denosumab

Advantages of Deno_____ (Simplicity): - dosing every 6 months

Denosumab

Advantages of Deno_____ (Price): - Can bill for administration fee at practice

Denosumab

Advantages of Denos___b (Efficacy): - 68% RRR in vertebral fracture at 3 years - 40% RRR in hip fracture at 3 years - 20% RRR in non-vertebral fractures at 3 years

Denosumab

Advantages of Den___mab (Safety): - Dose adjustment not needed in renal patients

Denosumab

Terip______e: Stimulates osteoblast number and function, Increase GI Ca absorption, Increase renal tubular reabsorption of Ca Indications: - Postmenopausal women at high risk for fracture - Men with primary or hypogonadal osteoporosis as high risk for fracture - Men and women at high risk of fracture on sustained systemic glucocorticoid therapy - Unresponsive or intolerant to other therapies

Teriparatide

The pharmacokinetics of single-dose terip______e were not significantly affected in adult patients with mild-to-moderate renal impairment, suggesting no need for dose adjustment

teriparatide

Contraindications of terip_______: should not be prescribed for patients who are at increased baseline risk for osteosarcoma (including those with Paget’s disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, or prior external beam or implant radiation therapy involving the skeleton).

Teriparatide

Ter_________: Treatment duration maximum of two years

Teriparatide

Advantages of Terip______e (Safety): - No increased risk of breast cancer or uterine cancer or VTE - Appears to be safe in moderate kidney impairment (40-49mL/min)

Teriparatide

Advantages of Terip_______ (Efficacy): - Increases in BMD of spine (9%) and hip (3%) - Decrease in vertebral (RR 65%) and non-vertebral (RR 35%) fractures

Teriparatide

Disadvantages of Terip______e (Safety): - osteosarcoma has been observed in animal studies - Contraindicated in patients with Paget's disease, open epiphyses, history of radiation involving skeleton, bone cancer or bone metastasis - unexplained elevations in alkaline phosphatase

Teriparatide

Disadvantages of Teripa______ (Tolerability): Nausea, HA, leg cramps, dizziness, injection site discomfort, hypercalcemia, hyperuricemia, orthostatic hypotension (1st few doses), muscle weakness, cramps If bone pain, seek medical attention

Teriparatide

Disadvantages of Teripa_____e (Efficacy): Treatment duration maximum of two years.

Teriparatide

Abalopa______ is a PTH analog which acts as an agonist at the PTH receptor. This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys, this had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral sites - Indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy Similar effectiveness and adverse event profile to teriparatide .. possibly with a lowr risk of hypercalcemia

Abaloparatide

Abalopar____e is a PTH analog which acts as an agonist at the PTH receptor. This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys, this had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral sites

Abaloparatide

Abalopa_____e: Indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy Similar effectiveness and adverse event profile to teriparatide .. possibly with a lowr risk of hypercalcemia

Abaloparatide

Romo______b is a humanized monoclonal antibody that inhibits the action of sclerostin, a regulatory factor in bone metabolism leading to increased bone formation and, to a lesser extent, decreased bone resorption - - Not considered initial therapy. Possible candidates include: - Patients with multiple fragility fractures - Those at high risk for fracture who cannot tolerate any other osteoporosis therapies - Those who fail other osteoporosis therapies (fracture with loss of BMD in spite of compliance with therapy). - In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE). Therapy should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. - The anabolic effect of R__________ wanes after 12 monthly doses of therapy. Therefore, the duration of use should be limited to 12 monthly doses - Must be administered by healthcare professional - Patients should be adequately supplemented with calcium and vitamin D during treatment

Romosozumab

Romos_____b: Not considered initial therapy. Possible candidates include - Patients at with multiple fragility fractures - Those at high risk for fracture who cannot tolerate any other osteoporosis therapies - Those who fail other osteoporosis therapies (fracture with loss of BMD in spite of compliance with therapy).

Romosozumab

- In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE). Therapy should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. - The anabolic effect of Romos___mab wanes after 12 monthly doses of therapy. Therefore, the duration of use should be limited to 12 monthly doses - Must be administered by healthcare professional - Patients should be adequately supplemented with calcium and vitamin D during treatment

Romosozumab

Calcitr___: This synthetic vitamin D analogue, which promotes calcium absorption, has been approved by the FDA for managing hypocalcemia and metabolic bone disease in renal dialysis patients. It is also approved for use in hypoparathyroidism, both surgical and idiopathic, and pseudohypoparathyroidism. No reliable data demonstrate a reduction of risk for osteoporotic fracture.

Calcitriol

Other bisp__________s (etidronate, pamidronate, tiludronate). These medications vary chemically from alendronate, ibandronate, risedronate and zoledronic acid but are in the same drug class. At this time, none is approved for prevention or treatment of osteoporosis.

bisphosphonates

Sod___ fluo____: Through a process that is still unclear, this stimulates the formation of new bone. The quality of bone mass thus developed is uncertain, and the evidence that it reduces fracture risk is conflicting and controversial.

Sodium fluoride

GIOP =

Glucocorticoid-induced osteoporosis

Glucocorticoid-induced osteoporosis =

GIOP

G__P: Most common secondary cause of osteoporosis and 3rd most common cause overall

GIOP

Regarding G__P: The American College of Rheumatology (ACR) recommends oral bisphosphonate therapy for all patients age 40 and over at moderate to high risk of fracture receiving glucocorticoids (prednisone 2.5 mg or more daily or equivalent) for 3 months or longer.

GIOP

Treatment for G__P regarding men and postmenopausal women: - Bisphosphonates as first-line therapy. Alendronate or risedronate preferred because of clinical trial data demonstrating efficacy - Zoledronic acid is an acceptable alternative for those intolerant of bisphosphonates or the dosing requirements - Teriparatide is reserved for patients with severe osteoporosis (T-score of -3.5 or below even in the absence of fractures or a T-score of -2.5 or below plus a fragility fracture), those who are unable to tolerate any of the available bisphosphonates or who continue to fracture after one year of bisphosphonate therapy.

GIOP

Treatment for G___ regarding premenopausal women: - Bisphosphonates as first-line therapy - Teriparatide is an alternative as long as epiphyses are fully fused and potential short and long-term risks, as well as potential effects on the fetus are considered - ¨Denosumab - Potential alternative in those with CI or intolerant to other therapies. NOT FDA approved

GIOP

For patients unable to take oral biphosphonates, alternative therapy in order are: 1) IV Biph___________ 2) Terap_______ 3) Denos____ 4) Ralox_____

1) IV Bisphosphonates 2) Teriparatide 3) Denosumab 4) Raloxifene

G___ is defined as an arthritis associated with the presence of monosodium urate crystals (MSU) in synovial fluid or tissue leading to inflammatory reaction that causes intense pain, erythema and joint swelling

Gout

H____________ is defined as serum uric acid as >7.0 mg/dL in ♂ and >6.0 mg/dL in ♀

Hyperuricemia

Regarding hyp__u_______: It is not recommended to treat an elevated serum uric acid concentration in an asymptomatic patient

Hyperuricemia

Many secondary causes of h____________ (which can lead to gout): - Overproduction: purine rich diet, EToH, fructose, myeloproliferative disorders. - Underexcretion: Ethanol, cyclosporine, thiazides, furosemide, ethambutol, pyrazinamide, levodopa, niacin, low dose ASA, CTX agents , CKD. - Other risk factors include weight, gender, HTN and others.

Hyperuricemia

Non-pharm treatment of g___/hyperuricemia: - Correction or modification of underlying factors - SEE secondary causes above - Medications, weight loss - Reduce dietary intake of purine-rich foods - Increase fluid intake - Decrease salt consumption - Joint rest / immobilization for 1-2 days - Application of ice to affected area

gout

For attacks of mild/moderate g___ severity (6 of 10 on a 0–10 pain VAS) particularly those involving 1 or a few small joints or 1 or 2 large joints, monotherapy is appropriate

gout

Regarding g___ treatment: No specific preference was given to NSAIDs, colchicine or corticosteroids as initial management in the absence of comorbidities - Current practice is often NSAIDs > colchicine > corticosteroids - Must consider patient specific factors and comorbidities

gout

- Current practice is often NSAIDs > colchicine > corticosteroids (regarding g___)

gout

Regarding g___: NSAIDs: Most effective if started within 1st 24 hours of onset and continued for 24 hours after resolution - All NSAIDs (except ASA and Tolmetin) are effective when given at full anti-inflammatory doses - Avoid use in Active peptic ulcer disease, Uncompensated congestive heart failure, Uncontrolled hypertension, Severe renal impairment (<30-35ml/min)

gout

Regarding g___: COXibs: The risk/benefit ratio is not yet clear for celecoxib in acute gout. - Option in patients with gastrointestinal contraindications or intolerance to NSAIDs

gout

Regarding gout: Colc______: Possesses no analgesic or uric acid lowering effects

Colchicine

Regarding gout and c_________: 1.2mg initially, then 0.6mg 1h later; total 1.8mg over 1 hour. - This "acute dosing regimen" should be avoided in renal and hepatic dysfunction and in the elderly and frail. - In patients with severe renal impairment (CrCl <30ml/min), this "acute dosing regimen" should not be repeated for 14 days. - CrCl 30-80ml/min. no renal adjustment necessary.

Colchicine

Colc______ place in therapy for gout: - NSAID intolerance - Patients at risk for NSAID induced gastropathy (active PUD) - Moderate CKD (with proper dose modifications) - Failed NSAID therapy

Colchicine

Regarding colc______ for gout: Many ADRs (mostly GI) and CIs (Severe renal/hepatic impairment, etc) - - Gastrointestinal (nausea, abdominal cramps, diarrhea) - Alopecia - Malabsorption of vitamin B12 - Myopathy - Myelosuppression - - CIs(Severe renal/hepatic impairment, etc) - Neutropenia - Severe renal/hepatic impairment - Concomitant use of a P-glycoprotein (P-gp) or strong CYP3A4 inhibitor in presence of renal or hepatic impairment - Severe cardiac / GI disease

Colchicine

Cor__________ds (regarding gout): Indicated with NSAIDS or colchicine contraindication (eg renal impairment) or treatment failure.

Corticosteroids

Corticosteroids and NSAIDs have been shown equally effective in acute g___ treatment

gout

Cor___________s (regarding gout): Used either systemically (PO/IV/IM) or by intraarticular injection.

Corticosteroids

Cort__________s (regarding gout): Rebound attacks are relatively common once glucocorticoids are withdrawn, especially in patients who have previously suffered a number of prior attacks, whose intercritical periods have progressively shortened, and who are not receiving prophylactic therapy. For this reason, slower tapering of the glucocorticoid dose with extension of the course to 10 to 14 or even 21 days is advisable in such patients.

Corticosteroids

Corti_________s (regarding gout) ADRs: Hyperglycemia, hypertension, headache, mood changes, fluid retention

Corticosteroids

Corti__________ (regarding gout) precautions: - Diabetes - Uncontrolled HTN - Severe infections - Active peptic ulcer disease - Severe cardiovascular disease (HF)

Corticosteroids

Inter______-1 (IL-1) inhi______ potentially have a role as anti-inflammatory agents in refractory gout or for patients who are unable to tolerate conventional therapy, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or glucocorticoids, for acute attacks - After NSAIDs, colchicine, and steroids, these are beneficial as fourth-line therapy for acute gout attacks due to their high cost and limited clinical experience

Interleukin-1 (IL-1) inhibitors

Regarding gout, Cort________n: Exogenous administration of intramuscular adrenocorticotropic hormone (ACTH) stimulates production of cortisol and corticosterone by the adrenal cortex.

Corticotropin

Cortico_____n (regarding gout): - May require several repeat injections and cannot be used in patients with recent prior use of systemic steroids, since the action of ACTH requires an unsuppressed adrenal axis - A dose of 40 IU given intramuscularly and repeated every eight to 24 hours, as needed - Issues: ACTH has not been shown to be any more effective than systemic corticosteroids and may require significantly more doses, even comparing IM to IM administration

Corticotropin

Regarding g___: Combination therapy: In severe polyarticular attacks, particularly attacks involving multiple large joints: - colchicine may be used in combination with an NSAID or oral corticosteroid - Intraarticular corticosteroid injections may be used in combination with any other first-line agent (NSAID, colchicine, oral corticosteroid)

gout

Non-pharm interventions for a____ g____ a________: - lose weight if obese - discontinue ETOH - low-purine diet - d/c contributing drugs if possible - maintain adequate hydration

acute gouty arthritis

Regarding g___: High purine foods: - sweetbreads - yeast (Baker's and Brewer's) - sardines, mackerel, anchovies, herring - organ meats, meat extracts, mincemeat - gravies - beer and alcoholic products - dried beans - mussels, scallops

gout

Regarding g___: Moderate purine foods: - wheat, wheat bran, oatmeal, bread - wheat germ, brown rice, whole grains - asparagus, cauliflower, spinach - mushrooms - green peas - lean meat - pultry without skin - tofu - fish, shellfish (shrimp, crab, oysters, clams) - meat soups and broths

gout

Regarding g___: Low purine diets are not well tolerated

gout

Regarding g___: While the ACR guidelines encourage patients to consume low/non-fat dairy products and vegetables, they also cite a lack of specific evidence

gout

Regarding g___: When to start a low purine diet: - May be started during an acute gout attack only if anti-inflammatory treatment is also initiated, because sudden shifts in SUA levels from mobilization of tissue urate stores may precipitate or exacerbate gouty arthritis OR - After resolution (4-6 week) of acute attack. Some clinicians may use colchicine or low dose NSAIDs prophylactically upon initiation until [serum UA] returns to normal or maximum of 3-6 months

gout

Xanthine oxidase inhibitors (e.g. allo_______) for gout: Reduces the serum uric acid level while increasing the renal excretion of the more soluble oxypurine precursors - Good for overproducers and underexcretors - 1st line

allopurinol

Febux____t: Reserved for those hypersensitive, intolerant or had failure with allopurinol. - Several clinically significant DIs

Febuxostat

Uricosurics (Probe_____): Blocks (competes with) uric acid reabsorption at the proximal convoluted tubule increasing the rate of uric acid excretion. - - Best efficacy with underexcretors - - CIs - Hypersensitivity reactions, renal dysfunction (Clcr <50m/min), history of kidney stones, acute attack, and overproducers of uric acid - - May share allergenicity with other classes of sulfonamide drugs

Probenicid

Uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4) inhibitor: Lesinurad - American College of Rheumatology states that serum urate concentrations in gout patients should be reduced sufficiently to result in durable improvement in signs and symptoms of the disease and recommends a target serum urate concentration of <6 mg/dL (or <5 mg/dL if necessary to achieve such clinical improvements). - Use in combination with xanthine oxidase inhibitor in patients who have not attained target serum uric acid concentrations - Do not use as monotherapy. - Ironwood discontinued U.S. commercialization of lesinurad (DUZALLO and ZURAMPIC), effective February 1, 2019

Lesinurad

Losar___ Increases uric acid secretion and urinary pH. - Option for hypertensive patients with gout

Losartan

Fibr___s (for gout): Increases uric acid secretion - Option for select patients with hypertriglyceridemia

Fibrates

Colc______ (for gout): Daily use (0.6-1.2mg/day) for prophylaxis. - Renal dosage adjustments required with CrCl < 30ml/min

Colchicine

Herbal treatments for g___: Anecdotal claims for many herbs but no acceptable clinical evidence of efficacy or safety

gout

Peglo_____e: FDA approved for the treatment of refractory chronic gout.

Pegloticase

Romosozumab is a humanized monoclonal antibody that inhibits the action of sclerostin, a regulatory factor in bone metabolism leading to increased bone formation and, to a lesser extent, decreases bone resorption

Bisp__________s: Any of a group of drugs used to limit the loss of bone density in conditions such as osteoporosis and bone cancer.

Bisphosphonates.

Module 6: Bone & Joint Disorders Flashcards

(146 cards)